Aptinyx (NASDAQ:APTX) initiates a Phase 2 clinical study of its NMDA receptor modulator, NYX-458, for the treatment of mild cognitive impairment associated with Parkinson’s disease.
Top-line data from the 135-patient study are expected in H2 2021.
The study will evaluate daily oral dosing of NYX-458 – 10 mg, 30 mg, or 100 mg – compared to placebo over a 12-week period.
The effects of NYX-458 on cognitive performance will be evaluated across multiple endpoints related to attention, memory, executive function, visuospatial deficits, and patient quality of life.
Shares are up 3% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.